Drug Trial Radar · NCT03742102
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
243
Actual
Start
Dec 21, 2018
Primary completion
Nov 29, 2024
Study completion Feb 26, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Conditions
- Triple Negative Breast Neoplasms
Interventions
DurvalumabDrug
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
CapivasertibDrug
Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
OleclumabDrug
Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
PaclitaxelDrug
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
Trastuzumab deruxtecanDrug
Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
Datopotamab deruxtecanDrug
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT) EventsTime frame: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Columbia, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Grand Rapids, Michigan
Research Site
St Louis, Missouri
Research Site
Dallas, Texas
Research Site
Williamsburg, Virginia
Research Site
Kelowna, British Columbia, Canada
Research Site
London, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Gdansk, Poland
Research Site
Krakow, Poland
Research Site
Lublin, Poland
Research Site
Opole, Poland
Research Site
Rzeszów, Poland
Research Site
Warsaw, Poland
Research Site
Warsaw, Poland
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Cambridge, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.